The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x L and Mcl-1

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1262-1274

  Yuan, Zhu ^a   Cao, Kang ^b   Lin, Chao ^a   Li, Lei ^a   Liu, Huan yi ^c   Zhao, Xin yu ^a   Liu, Lei ^a   Deng, Hong xin ^a   Li, Jiong ^a   Nie, Chun lai ^a   Wei, Yu quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

^c CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CISPLATIN; LIPOSOME; PLASMID DNA; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; PUMA PROTEIN; RECOMBINANT PUMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; DELETION MUTANT; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYTOCHROMES C; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE DELETION; HUMANS; IN SITU NICK-END LABELING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82855168143     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00176     Document Type: Article

References (69)

1. Jemal A, et al. (2006) Cancer statistics. CA Cancer J. Clin. 56:106-30.
2. Banks E. (2000) The Epidemiology of Ovarian Cancer. In: Ovarian Cancer: Methods and Protocols. Bartlett JMS (ed.) Totowa (NJ): Humana Press, pp. 3-12.
3. Malpas JS. (1979) Chemotherapy in the management of ovarian cancer: a review. J. R. Soc. Med. 72:357-61.
4. Reed E. (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 24:331-44.
5. Cohen SM, Lippard SJ. (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 67:93-130.
6. Tanabe M, et al. (2003) Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res. 63:8592-5.
7. Johnstone RW, Ruefli AA, Lowe SW. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153-64.
8. Yu J, Zhang L. (2004) Apoptosis in human cancer cells. Curr. Opin. Oncol. 16:19-24.
9. Hanahan D, Weinberg RA. (2000) The hallmarks of cancer. Cell. 100:57-70.
10. Milner BJ, et al. (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53:2128-32.
11. Reles A, et al. (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7:2984-97.
12. Vogelstein B, Lane D, Levine AJ. (2000) Surfing the p53 network. Nature. 408:307-10.
13. Lane DP, Lain S. (2002) Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8:S38-42.
14. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell. 7:673-82.
15. Nakano K, Vousden KH. (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683-94.
16. Han J, et al. (2001) Expression of bbc3, a proapoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc. Natl. Acad. Sci. U. S. A. 98:11318-23.
17. Labi V, Erlacher M, Kiessling S, Villunger A. (2006) BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ. 13:1325-38.
18. Yu J, Zhang L. (2008) PUMA, a potent killer with or without p53. Oncogene. 27 Suppl 1:S71-83.
19. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. (2003) PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100:1931-6.
20. Ming L, Wang P, Bank A, Yu J, Zhang L. (2006) PUMA dissociates Bax and BCL-XL to induce apoptosis in colon cancer cells. J. Biol. Chem. 281:16034-42.
21. Erlacher M, et al. (2006) Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J. Exp. Med. 203:2939-51.
22. Nelson DA, et al. (2004) Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 18:2095-107.
23. Michalak EM, et al. (2009) Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 16:684-96.
24. Yu J, Yue W, Wu B, Zhang L. (2006) PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin. Cancer Res. 12:2928-36.
25. Sun Q, Sakaida T, Yue W, Gollin SM, Yu J. (2007) Chemosensitization of head and neck cancer cells by PUMA. Mol. Cancer Ther. 6:3180-8.
26. Wang H, et al. (2006) Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol. Ther. 5:380-5.
27. Wang R, et al. (2009) Tumor-specific adenovirusmediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 117:45-54.
28. Al-Bahlani S, et al. (2011) P73 regulates cisplatininduced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene. Apr 25. [Epub ahead of print]
29. Liu YY, et al. (2011) Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res. 71:2276-85.
30. Yang G, et al. (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res. 16:3875-86.
31. Gallardo D, Drazan KE, McBride WH. (1996) Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56:4891-3.
32. Villedieu M, et al. (2007) Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol. Oncol. 105:31-44.
33. Sasaki H, Sheng YL, Kotsuji F, Tsang BK. (2000) Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 60:5659-66.
34. Williams J, et al. (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol. 96:287-95.
35. Su JM, et al. (2003) Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. 63:600-7.
36. Yuan Z, et al. (2009) Improved therapeutic efficacy against murine carcinoma by combining honokiol with gene therapy of PNAS-4, a novel pro-apoptotic gene. Cancer Sci. 100:1757-66.
37. Blezinger P, et al. (1999) Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17:343-8.
38. Wei YQ, et al. (1994) Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res. 54:4952-7.
39. ΔΔCt method. Methods. 25:402-8.
40. Ruiz-Vela A, Opferman JT, Cheng EH, Korsmeyer SJ. (2005) Proapoptotic BAX and BAK control multiple initiator caspases. EMBO Rep. 6:379-85.
41. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6:443-50.
42. Zhang R, et al. (2006) Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther. 13:1263-71.
43. Lin X, et al. (2007) Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol. 104:540-6.
44. Kaplanand EL, Meier P. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-81.
45. Peto R, Pelo J. (1972) Asymptotically efficient rank invariant test procedures. J. Roy. Stat. Soc. Ser. A. Gene. 135:185-206
46. Jeffers JR, et al. (2003) Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 4:321-8.
47. Liu JR, et al. (1998) Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70:398-403.
48. Marone M, et al. (1998) bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin. Cancer Res. 4:517-24.
49. Kassim SK, et al. (1999) Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin. Biochem. 32:333-8.
50. Dodier P, Piché A. (2006) Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. Gynecol. Oncol. 100:254-63.
51. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR. (2000) BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br. J. Cancer. 82:436-40.
52. Simonin K, et al. (2009) Mcl-1 is an important determinant of the apoptotic response to the BH3- mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol. Cancer Ther. 8:3162-70.
53. Herrant M, et al. (2004) Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene. 23:7863-73.
54. Weng C, Li Y, Xu D, Shi Y, Tang H. (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- induced apoptosis in Jurkat leukemia T cells. J. Biol. Chem. 280:10491-500.
55. Maurer U, et al. (2006) Glycogen synthase kinase- 3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell. 21:749-60.
56. Adams KW, Cooper GM. (2007) Rapid turnover of Mcl-1 couples translation to cell survival and apoptosis. J. Biol. Chem. 282:6192-200.
57. Agarwal R, Linch M, Kaye SB. (2006) Novel therapeutic agents in ovarian cancer. Eur. J. Surg. Oncol. 32:875-86.
58. Kojima H, et al. (1998) Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem. 273:16647-50.
59. Yang Z, et al. (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 12:5817-25.
60. Li P, et al. (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479-89.
61. Asselin E, Mills GB, Tsang BK. (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61:1862-8.
62. Henkels KM, Turchi JJ. (1999) Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 59:3077-83.
63. Blanc C, et al. (2000) Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res. 60:4386-90.
64. Yang X, et al. (2006) Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66:3126-36.
65. Fricker M, O'Prey J, Tolkovsky AM, Ryan KM. (2010) Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis. 1:e59.
66. Callus BA, et al. (2008) Triggering of apoptosis by puma is determined by the threshold set by prosurvival Bcl-2 family proteins. J. Mol. Biol. 384:313-23.
67. Corina L, Pilar J, Ana B, Jesús E, Alberto O. (2005) Role of Bcl-xL in paracetamol-induced tubular epithelial cell death. Kidney Int. 67:592-601.
68. Ji LL, Chen Y, Liu TY, Wang ZT. (2008) Involvement of Bcl-xL degradation and mitochondrialmediated apoptotic pathway in pyrrolizidine alkaloids- induced apoptosis in hepatocytes. Toxicol. Appl. Pharmacol. 231:393-400.
69. Droga-Mazovec G, et al. (2008) Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 283:19140-50.